Tower Research Capital LLC TRC Increases Stake in Achieve Life Sciences, Inc. (NASDAQ:ACHV)

Tower Research Capital LLC TRC grew its stake in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 185.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,545 shares of the biopharmaceutical company’s stock after acquiring an additional 4,905 shares during the period. Tower Research Capital LLC TRC’s holdings in Achieve Life Sciences were worth $27,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its stake in Achieve Life Sciences by 7.2% in the 4th quarter. Wells Fargo & Company MN now owns 74,933 shares of the biopharmaceutical company’s stock worth $264,000 after acquiring an additional 5,059 shares during the last quarter. LPL Financial LLC boosted its position in Achieve Life Sciences by 2.9% during the fourth quarter. LPL Financial LLC now owns 196,833 shares of the biopharmaceutical company’s stock valued at $693,000 after buying an additional 5,500 shares during the period. Barclays PLC boosted its stake in shares of Achieve Life Sciences by 12.2% during the fourth quarter. Barclays PLC now owns 53,473 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 5,818 shares during the period. Geode Capital Management LLC grew its holdings in Achieve Life Sciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 755,845 shares of the biopharmaceutical company’s stock worth $2,661,000 after acquiring an additional 6,736 shares during the last quarter. Finally, SG Americas Securities LLC increased its holdings in Achieve Life Sciences by 74.8% during the 4th quarter. SG Americas Securities LLC now owns 19,886 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 8,512 shares during the period. Hedge funds and other institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Price Performance

Shares of Achieve Life Sciences stock opened at $2.73 on Friday. The business has a 50 day moving average of $2.48 and a 200 day moving average of $3.32. Achieve Life Sciences, Inc. has a 52 week low of $1.84 and a 52 week high of $5.59. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.31. The company has a market cap of $94.69 million, a PE ratio of -2.42 and a beta of 1.49.

Achieve Life Sciences (NASDAQ:ACHV) last released its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.37) EPS for the quarter, meeting analysts’ consensus estimates of ($0.37). As a group, equities research analysts forecast that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current year.

Insider Activity

In other Achieve Life Sciences news, CFO Mark K. Oki acquired 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $2.89 per share, with a total value of $28,900.00. Following the transaction, the chief financial officer now owns 10,000 shares of the company’s stock, valued at $28,900. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 2.00% of the company’s stock.

Achieve Life Sciences Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.